<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02284880</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-130</org_study_id>
    <nct_id>NCT02284880</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate</brief_title>
  <official_title>Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory
      blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female
      subjects, to demonstrate the bioequivalence (BE) between two active product ingredient (API)
      sources of eslicarbazepine acetate (ESL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I, two-centre, open-label, randomized, gender-balanced, single-dose, laboratory
      blinded, two-period, two-sequence, crossover study in 2 groups of 20 healthy male and female
      subjects. The study consisted in 2 periods separated by a wash-out of at least 7 days
      between doses. To demonstrate the bioequivalence (BE) between two active product ingredient
      (API) sources [current API source - marketed formulation (MF) versus new API source -
      to-be-marketed (TBM)] of eslicarbazepine acetate (ESL)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax - Maximum Plasma Concentration</measure>
    <time_frame>pre-dose then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose on each dosing period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed BIA 2-005 - BIA 2-093 metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax - Time of Occurrence of Cmax</measure>
    <time_frame>pre-dose then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose on each dosing period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed
BIA 2-005 - BIA 2-093 metabolite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Sampling Time at Which Concentrations Were at or Above the Limit of Quantification</measure>
    <time_frame>pre-dose then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose on each dosing period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed
BIA 2-005 - BIA 2-093 metabolite</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Group 1 BIA 2-093</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomly received on period 1 and 2, either a single 400 mg tablet of ESL (MF - marketed formulation), or a single 400 mg tablet of ESL (TBM - o-be-marketed);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 BIA 2-093</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomly received on period 1 and 2, either a single 800 mg tablet of ESL (MF - marketed formulation), or a single 800 mg dose of ESL (TBM - o-be-marketed).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <description>MF - Marketed formulation</description>
    <arm_group_label>Group 1 BIA 2-093</arm_group_label>
    <arm_group_label>Group 2 BIA 2-093</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <description>TBM - to-be-marketed</description>
    <arm_group_label>Group 1 BIA 2-093</arm_group_label>
    <arm_group_label>Group 2 BIA 2-093</arm_group_label>
    <other_name>ESL, Eslicarbazepine acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated informed consent form before any study-specific screening
             procedure was performed,

          -  Healthy male or female 18 to 55 of age, inclusive,

          -  Had a BMI within the range of 18 to 25 kg/m2 inclusive at screening,

          -  Had a physical examination, vital signs, electrocardiogram (ECG) and routine
             laboratory tests within normal ranges or considered as non clinically significant
             (NCS) by the Investigator,

          -  Non-smokers or smokers of less than 10 cigarettes per day,

          -  If female, she was not of childbearing potential by reason of surgery (hysterectomy,
             bilateral oophorectomy or tubal ligation) or, if of childbearing potential, she had
             to be using one of the following effective method of contraception (intrauterine
             device (IUD) or abstention or condom) for the duration of the trial and had to have a
             negative urine pregnancy test at screening visit and upon each admission period.

        Exclusion Criteria:

          -  Had a clinically relevant history or presence of respiratory, gastrointestinal,
             renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric,
             musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective
             tissue disease or disorders, or have a clinically relevant surgical history,

          -  Presented any disease or condition (medical or surgical) which, in the opinion of the
             Investigator, that may have interfered with the absorption, distribution, metabolism
             or excretion of study drug,

          -  Had a history of relevant atopy or any drug hypersensitivity (including known
             hypersensitivity to eslicarbazepine acetate or any of its excipients),

          -  Had a history of alcoholism or drug abuse within 1 year before D 1,

          -  Consumption of more than 50 g of ethanol per day (12.5 Centiliters [cL] glass of 10°
             [10%] wine = 12 g; 4 cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%]
             beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g),

          -  Use of medicines within 2 weeks of admission to first treatment period that could
             affect, in the Investigator's opinion, the safety of the subject,

          -  Had used any investigational drug or participated in any clinical trial within 2
             months of admission to first treatment period,

          -  Had donated or received any blood or blood products within 2 months prior to
             screening,

          -  Could not communicate reliably with the investigator, was unlikely to co-operate with
             the requirements of the study,

          -  Was unwilling or unable to give written informed consent,

          -  If female, was pregnant or breast-feeding,
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 7, 2015</lastchanged_date>
  <firstreceived_date>November 4, 2014</firstreceived_date>
  <firstreceived_results_date>December 10, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>400 mg BIA 2-093 Group 1</title>
          <description>In Group 1, subjects received on period 1 and 2: 400 mg BIA 2-093 ESL: MF first, then TBM</description>
        </group>
        <group group_id="P2">
          <title>400 mg BIA 2-093 Group 2</title>
          <description>In Group 2, subjects received on period 1 and 2: 400 mg BIA 2-093 ESL: TBM first, then MF</description>
        </group>
        <group group_id="P3">
          <title>800 mg BIA 2-093 Group 1</title>
          <description>In Group 1, subjects received on period 1 and 2: 400 mg BIA 2-093 ESL: MF first, then TBM</description>
        </group>
        <group group_id="P4">
          <title>800 mg BIA 2-093 Group 2</title>
          <description>In Group 2, subjects received on period 1 and 2: 400 mg BIA 2-093 ESL: TBM first, then MF</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>First Period (4 Days)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Wash-out Period (7 Days)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Second Period (4 Days)</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>400 mg BIA 2-093</title>
          <description>In Group 1, subjects received randomly on period 1 and 2, either a single 400 mg tablet of ESL (MF), or a single 400 mg tablet of ESL (TBM).</description>
        </group>
        <group group_id="B2">
          <title>800 mg BIA 2-093</title>
          <description>In Group 2, subjects received randomly on period 1 and period 2, either a single 800 mg tablet of ESL (MF), or a single 800 mg dose of ESL (TBM).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Plasma Concentration</title>
        <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed BIA 2-005 - BIA 2-093 metabolite</description>
        <time_frame>pre-dose then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose on each dosing period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>400 mg BIA 2-093</title>
            <description>In Group 1, subjects received randomly on period 1 and 2, either a single 400 mg tablet of ESL (MF), or a single 400 mg tablet of ESL (TBM).</description>
          </group>
          <group group_id="O2">
            <title>800 mg BIA 2-093</title>
            <description>In Group 2, subjects received randomly on period 1 and period 2, either a single 800 mg tablet of ESL (MF), or a single 800 mg dose of ESL (TBM).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cmax - Maximum Plasma Concentration</title>
            <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed BIA 2-005 - BIA 2-093 metabolite</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Cmax (BIA 2-005 Reference)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6461" spread="1346"/>
                  <measurement group_id="O2" value="13183" spread="2564"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Cmax (BIA 2-005 Test)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6547" spread="1524"/>
                  <measurement group_id="O2" value="12988" spread="2215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax - Time of Occurrence of Cmax</title>
        <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed
BIA 2-005 - BIA 2-093 metabolite</description>
        <time_frame>pre-dose then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose on each dosing period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>400 mg BIA 2-093</title>
            <description>In Group 1, subjects received randomly on period 1 and 2, either a single 400 mg tablet of ESL (MF), or a single 400 mg tablet of ESL (TBM).</description>
          </group>
          <group group_id="O2">
            <title>800 mg BIA 2-093</title>
            <description>In Group 2, subjects received randomly on period 1 and period 2, either a single 800 mg tablet of ESL (MF), or a single 800 mg dose of ESL (TBM).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Tmax - Time of Occurrence of Cmax</title>
            <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed
BIA 2-005 - BIA 2-093 metabolite</description>
            <units>hours</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <sub_title>Tmax (BIA 2-005 Reference)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.00" lower_limit="0.50" upper_limit="6.00"/>
                  <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="4.02"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Tmax (BIA 2-005 Test)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.00" lower_limit="0.50" upper_limit="6.00"/>
                  <measurement group_id="O2" value="1.75" lower_limit="1.00" upper_limit="6.00"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Sampling Time at Which Concentrations Were at or Above the Limit of Quantification</title>
        <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed
BIA 2-005 - BIA 2-093 metabolite</description>
        <time_frame>pre-dose then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours post-dose on each dosing period</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>400 mg BIA 2-093</title>
            <description>In Group 1, subjects received randomly on period 1 and 2, either a single 400 mg tablet of ESL (MF), or a single 400 mg tablet of ESL (TBM).</description>
          </group>
          <group group_id="O2">
            <title>800 mg BIA 2-093</title>
            <description>In Group 2, subjects received randomly on period 1 and period 2, either a single 800 mg tablet of ESL (MF), or a single 800 mg dose of ESL (TBM).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>AUC0-t - Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to the Last Sampling Time at Which Concentrations Were at or Above the Limit of Quantification</title>
            <description>Reference - MF - marketed formulation Test - TBM - to-be-marketed
BIA 2-005 - BIA 2-093 metabolite</description>
            <units>ng.hr/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>AUC0-t (BIA 2-005 Reference)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="112568" spread="23011"/>
                  <measurement group_id="O2" value="279035" spread="60183"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AUC0-t (BIA 2-005 Test)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="108224" spread="23971"/>
                  <measurement group_id="O2" value="278734" spread="61738"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Before Treatment</title>
          <description>Before treatment with ESL ESL - Eslicarbazepine acetate, BIA 2-093</description>
        </group>
        <group group_id="E2">
          <title>400 mg Tablet of ESL (MF)</title>
          <description>400 mg tablet of ESL (MF) ESL - Eslicarbazepine acetate, BIA 2-093 MF - Marketed formulation</description>
        </group>
        <group group_id="E3">
          <title>400 mg Tablet of ESL (TBM)</title>
          <description>400 mg tablet of ESL (TBM) ESL - Eslicarbazepine acetate, BIA 2-093 TBM - To be marketed</description>
        </group>
        <group group_id="E4">
          <title>800 mg Tablet of ESL (MF)</title>
          <description>800 mg tablet of ESL (MF) ESL - Eslicarbazepine acetate, BIA 2-093 MF - Marketed formulation</description>
        </group>
        <group group_id="E5">
          <title>800 mg Tablet of ESL (TBM)</title>
          <description>800 mg tablet of ESL (TBM) ESL - Eslicarbazepine acetate, BIA 2-093 TBM - To be marketed</description>
        </group>
        <group group_id="E6">
          <title>After Follow-up Visit</title>
          <description>After Follow-up visit ESL - Eslicarbazepine acetate, BIA 2-093 MF - Marketed formulation TBM - To be marketed</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation delayed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
